Table 1.
Baseline characteristics of participants.
|
|
Age (years) | Parkinson disease duration (years) | Movement Disorder Society—Unified Parkinson’s Disease Rating Scale Section III (0-132)a | Hoehn and Yahr scale (1-5)a | Mini Mental State Examination (0-30)b | Trail Making Test part A (seconds)a | Trail Making Test part B (seconds)a | New Freezing of Gait Questionnaire (0-28)a | Parkinson Anxiety Scale (0-48)a | Timed Up and Go Test (seconds)a | Number of falls in the past year | Levodopa equivalent daily dose (mg) |
| P1 | 81 | 12 | 53 | 3 | 26 | 79.0 | 351.0 | 22 | 14 | 27.0 | 4 | 1120 |
| P2 | 62 | 14 | 18 | 2 | 30 | 14.9 | 26.9 | 24 | 9 | 10.4 | 1 | 2083c |
| P3d | 61 | 18 | 40 | 3 | 30 | 18.9 | 49.9 | 22 | 10 | 12.9 | 6 | 724 |
| P4 | 78 | 11 | 29 | 2 | 30 | 49.0 | 169.0 | 15 | 10 | 12.3 | 6 | 1300 |
| P5 | 76 | 5 | 45 | 2 | 29 | 13.0 | 130.2 | 11 | 11 | 12.9 | 1 | 600 |
| P6 | 75 | 8 | 27 | 2 | 28 | 59.0 | 106.0 | 17 | 18 | 13.9 | 0 | 900 |
| P7 | 66 | 16 | 35 | 3 | 25 | 41.4 | 284.5 | 23 | 29 | 15.3 | Approximately 550e | 600f |
| P8 | 60 | 10 | 47 | 2 | 29 | 62.0 | 87.0 | 24 | 40 | 14.5 | 6 | 1048 |
| P9g | 72 | 23 | 22 | 3 | 28 | 28.6 | 95.0 | 21 | 3 | 9.4 | Approximately 230h | 1694 |
| P10g | 75 | 16 | 57 | 2 | 28 | 49.4 | 149.9 | 21 | 20 | 14.0 | 0 | 400 |
| Value, mean (SD) |
70.6 (7.7) |
13.3 (5.2) |
37.3 (13.3) |
2.4 (0.5) |
28.3 (1.7) |
41.5 (22.2) |
144.9 (101.7) |
20.0 (4.3) |
16.4 (11.0) |
14.3 (4.8) |
N/Ai | 1046.9 (527.6) |
aLower scores are better.
bHigher scores are better.
cThis participant is on Duodopa therapy.
dThis participant withdrew because of medical reasons unrelated to the trial.
eThis participant reported 1 to 2 falls per day.
fThis participant received deep brain stimulation.
gThis participant did not receive the complete intervention because of COVID-19 lockdown.
hThis participant reported 4 to 5 falls per week.
iN/A: not applicable.